BMRN stock forecast, quote, news & analysis
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases... Show more
BioMarin Pharmaceutical Inc. (BMRN) Stock Analysis: Amicus Acquisition Ignites Portfolio Expansion
Key Takeaways
- BioMarin completed its $4.8 billion acquisition of Amicus Therapeutics, bolstering its rare disease portfolio with assets like Galafold.
- Analysts consensus leans Buy, with an average price target of $90, suggesting over 65% upside from current levels.
- Q1 2026 earnings set for May 4, with expectations for continued revenue growth from enzyme therapies and Voxzogo.
- Recent board leadership transition appoints Ian Clark as Chair, signaling strategic continuity.
- 2025 full-year revenues reached $3.2 billion, up 13% year-over-year, driven by core products.
Current Market Snapshot
BioMarin Pharmaceutical Inc. (BMRN) stock has navigated choppy waters in recent weeks, trading near the lower end of its 52-week range amid broader biotech sector pressures and pre-earnings positioning. Despite a modest year-to-date advance reflecting robust revenue momentum from enzyme therapies and Voxzogo (vosoritide for achondroplasia), shares have pulled back in the latest trading sessions. Average daily volume remains steady, underscoring investor interest ahead of key catalysts. The low beta of 0.29 highlights relative stability compared to the market, positioning BMRN as a defensive play in volatile healthcare conditions.
Trending AI Robots
Tickeron hosts hundreds of AI trading bots that analyze and trade thousands of tickers across diverse strategies, timeframes, and market conditions—from short-term scalping on 5-minute charts to swing trades over 60 minutes. The curated Trending AI Robots section spotlights 25 elite performers best suited to today's volatility, with annualized returns ranging from 24% to over 160%, win rates spanning 51% to 88%, and strong profit factors indicating reliability. These bots target hot sectors like semiconductors (e.g., NVDA, AMD), data centers, space, industrials, small caps, and gold miners, often using take-profit/stop-loss corridors for risk management. Whether you're a pattern day trader or long-term investor, reviewing these stats can reveal adaptive tools for current trends—explore the page to identify bots matching your risk profile and timeframe.
Recent Developments Driving BMRN Price Action
The past 30 days have been transformative for BioMarin Pharmaceutical Inc. (BMRN), headlined by the completion of its $4.8 billion acquisition of Amicus Therapeutics on April 27. This deal, cleared regulatorily on April 23, adds Galafold (migalastat) for Fabry disease and other rare disease assets, significantly diversifying BioMarin's enzyme replacement therapy (ERT) portfolio and enhancing long-term revenue potential. The announcement initially spurred optimism, but shares hovered around $54 amid broader biotech selloffs and profit-taking, reflecting tempered immediate market reaction despite strategic upside.
Analyst activity intensified post-acquisition. Morgan Stanley resumed coverage on April 27 with an Overweight rating and $120 price target, citing portfolio expansion. Piper Sandler maintained Buy on April 24, while RBC Capital held Sector Perform (Hold) on April 8. Consensus remains bullish, with 24-27 analysts averaging $90 targets, implying substantial upside. These updates countered short-term sentiment dips, as evidenced by a 2.4% one-month decline tied to sector rotation away from healthcare.
Corporate governance evolved with the April 21 appointment of Ian Clark as Board Chair, bringing experienced leadership from prior CEO roles to guide integration efforts. BioMarin also scheduled its Q1 2026 earnings for May 4 (4:30 p.m. ET), with analysts projecting EPS of $0.74 and revenues around $755 million—building on 2025's 13% growth to $3.2 billion. Pre-earnings caution likely contributed to recent price consolidation, as investors await guidance incorporating Amicus contributions expected in Q2.
Macro factors, including healthcare sector volatility and interest rate sensitivities, pressured biotech stocks, amplifying BMRN's 5% three-month drop. However, the company's $1.56 billion cash position and low debt-to-equity (10.56%) provide a solid buffer for execution. Overall, these developments shifted sentiment toward growth, though near-term price action reflects cautious positioning.
2026 Outlook and Key Factors to Monitor
BioMarin's 2026 trajectory hinges on seamless Amicus integration, with February guidance (pre-acquisition) projecting $3.325-$3.425 billion in revenues, including $2.225-$2.275 billion from enzyme therapies and Voxzogo expansion. Post-deal, combined portfolios position the company for accelerated rare disease market share, particularly in Fabry and achondroplasia.
Investors should track pipeline milestones across central nervous system (CNS), cardiovascular, musculoskeletal, and metabolic areas, including label expansions for PALYNZIQ (phenylketonuria, PKU) and vosoritide, plus gene therapy advancements like BMN 333 in achondroplasia trials. Regulatory catalysts from the U.S. Food and Drug Administration (FDA) remain pivotal, alongside competitive dynamics in rare diseases.
Risks include integration challenges, clinical trial outcomes (e.g., prior Voxzogo study halts), and macroeconomic pressures on biotech funding. Opportunities lie in Voxzogo's real-world data durability and untapped markets, with cost efficiencies from scale supporting R&D. Balanced monitoring of earnings updates, FDA interactions, and peer performance will inform strategic positioning through the year.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
BMRN's RSI Oscillator ascending out of oversold territory
The RSI Indicator for BMRN moved out of oversold territory on May 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 31 similar instances when the indicator left oversold territory. In of the 31 cases the stock moved higher. This puts the odds of a move higher at .
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on May 29, 2026. You may want to consider a long position or call options on BMRN as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for BMRN just turned positive on May 22, 2026. Looking at past instances where BMRN's MACD turned positive, the stock continued to rise in of 49 cases over the following month. The odds of a continued upward trend are .
BMRN moved above its 50-day moving average on June 03, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BMRN crossed bullishly above the 50-day moving average on June 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 19 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BMRN advanced for three days, in of 285 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 50-day moving average for BMRN moved below the 200-day moving average on May 07, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BMRN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
BMRN broke above its upper Bollinger Band on May 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BMRN entered a downward trend on May 08, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BMRN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.766) is normal, around the industry mean (19.817). P/E Ratio (40.842) is within average values for comparable stocks, (36.300). Projected Growth (PEG Ratio) (0.698) is also within normal values, averaging (1.691). BMRN has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). P/S Ratio (3.461) is also within normal values, averaging (355.038).
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BMRN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of innovative pharmaceuticals for serious diseases & medical conditions
Industry Biotechnology